From bugs to behavior: targeting the gut-brain interface for addiction therapeutics
Related Experiment Video
Updated: Jan 13, 2026

Rodent Brain Microinjection to Study Molecular Substrates of Motivated Behavior
Published on: September 16, 2015
Yiping Ru1,2, Jie Jia1,3, Xiyao Yang4
1NHC Key Laboratory of Drug Addiction Medicine, Kunming Medical University, Kunming, Yunnan, China.
Abstract:
Substance use disorders involving alcohol, cocaine, tobacco, opioids, and methamphetamine represent a significant global health burden, driven by the dysregulation of neurobiological and metabolic pathways in addiction. Emerging research highlights the gut-brain axis (GBA) as a critical mediator of addictive behaviors, with gut microbiota and their metabolites influencing bidirectional communication between the gastrointestinal tract and the central nervous system. This review synthesizes current evidence on how gut microbial communities modulate the brain's reward circuitry and the metabolism of addictive substances, thereby shaping behavioral and physiological responses to substance use. We explore the mechanistic interplay between microbial-derived metabolites (e.g., short-chain fatty acids, neurotransmitters) and host neuroimmune signaling, which may reinforce compulsive drug-seeking behaviors. Additionally, we discuss how chronic substance exposure alters gut microbiota composition and intestinal barrier integrity, perpetuating a vicious cycle of addiction. By reframing addiction through the lens of the GBA, this review highlights the therapeutic potential of microbiota-targeted interventions, such as probiotics, prebiotics, and dietary modulation, to restore gut-brain homeostasis and mitigate relapse. These insights advocate for a paradigm shift in understanding addiction as a systemic disorder, offering novel avenues for biomarker discovery and personalized treatment strategies.
Related Concept Videos
Drug Abuse and Addiction: Pharmacological Phenomena
Neurochemical Transmission: Sites of Drug Action
CNS Depressants: Alcohol and Nicotine
Ligand-Gated Ion Channel Receptor: Gating Mechanism
Drugs Affecting GI Tract Motility: Serotonin Receptor Agonists
Drugs for Treatment of Diarrhea-Predominant IBS
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...

